Project uptown Basel taking shape
A competence center for Industry 4.0 is being created on the former site of ABB. Private investors have contributed around half a million Swiss francs to the project. The foundation stone has now been officially laid.
Model of the Competence Center for Industry 4.0 (img. Fankhauser Arealentwicklungen)
The Schorenareal extends over an area of 70,000m2 and lies between the motorway and railway line, just a few hundred meters from Münchenstein station. For decades, it was home to manufacturing by ABB’s predecessor BBC. In 2016, the canton sold the site to Basel lawyer and investor Thomas Staehelin, President of the Chamber of Commerce of the two Basel cantons at the time. With uptown Basel AG, it is establishing a competence center for Industry 4.0. Construction began in March, with the foundation stone for phase one officially laid last Friday. The first building will offer lettable space of 25,000m2 over five floors, of which 70 percent has already leased, as site developer Hans-Jörg Fankhauser revealed in an article by the Basler Zeitung newspaper.
Around 500 million francs is being invested in the development by uptown Basel AG, which is expected to create approximately 2,000 jobs. With Axians and Bouygues, two major European technology companies are confirmed as moving to uptown. Cumulatively, they intend to offer 400 jobs at this site.
The economic director of Basel-Land Thomas Weber speaks of a renaissance for industry in the canton. “A quantum leap has been achieved with Staehelin’s project” he says in the newspaper article. “The historic potential of the site has been perfectly transformed for the future.”
The first building will be completed at the end of 2021. A further 10,000m2 of lettable space will follow down the line.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More